Restructuring

In July 2016, the Company announced a strategic restructuring under which Yield10 Bioscience has become its core business and the biopolymer operations were discontinued. As part of its strategic restructuring, the Company reduced staffing levels to twenty full-time employees as of December 31, 2016, and in January 2017, the Company formally changed its name to Yield10 Bioscience, Inc.. See Note 15, Discontinued Operations.

In connection with the wind down of biopolymer operations, the Company also ceased pilot production of biopolymer materials and reached agreements with the owner-operators of its biopolymer production facilities regarding the termination of these services. During 2016, the Company made cash payments of $1,023, issued 275,000 shares of company common stock with a fair market value of $85 and transferred certain biopolymer-related production equipment with a net book value of $111 to settle a portion of these agreements and other restructuring activities. Remaining cash restructuring costs at December 31, 2016, of $2,048 are expected to be paid out at various times through May 2018.



	Biopolymer Production Agreements			Employee Severance and Related Costs			Total
Original Charges and Amounts Accrued	$	2,641		$	322		$	2,963
Adjustments to Charges	—			562			562
Paid in Cash	(1,023		)	(258		)	(1,281		)
Paid through Stock and Equipment	(196		)	—			(196		)
Ending Balance Accrued at December 31, 2016	$	1,422		$	626		$	2,048

With the exception of approximately $238 of employee severance and related costs incurred for non-biopolymer employees, total restructuring costs shown in the table above have been classified within discontinued operations in the Company's consolidated statement of operations for the year ended December 31, 2016. Amounts related to the biopolymer production agreements are included in research and development expenses within discontinued operations as shown in Note 15. Remaining unpaid manufacturing contract termination costs of $933 and $489 are included in accrued expenses and contract termination obligation in the Company's consolidated balance sheet at December 31, 2016. Employee severance and related costs shown in the table above, are included in accrued expenses in the Company's consolidate balance sheet at December 31, 2016.